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The bifunctional mammalian mRNA capping enzyme (Mce1) consists of an N-terminal triphosphatase domain Mce1(1–210)
fused to a C-terminal guanylyltransferase domain Mce1(211–597). The physical domain order H2N-triphosphatase-guanylyl-
transferase-COOH mimics the temporal order of the capping reactions. To determine if the physical domain order is
functionally important in vivo, we engineered an “inverted” mammalian capping enzyme InvMce1 [H2N-Mce1(211–597)-(1–
210)-COOH]. We found that InvMce1 complemented the growth of Saccharomyces cerevisiae cet1 and ceg1 strains in
which the endogenous yeast triphosphatase and guanylyltransferase genes were deleted. By testing truncated versions of
InvMce1, we determined that Mce1(1–178) comprises a minimal functional triphosphatase domain. Baculovirus phosphatase
(BVP) is a monofunctional single-domain protein with RNA triphosphatase and RNA diphosphatase activities and an
undefined role in viral RNA metabolism. Here we demonstrated that BVP can function as an RNA triphosphatase for cap
formation in vivo when fused to the C-terminus of Mce1(211–597). By characterizing a series of InvMce1-BVP derivatives with
amino acid substitutions in the phosphate-binding loop of BVP, we showed that the in vivo activity of the mutant chimeras in
cap formation is contingent upon in vitro phosphohydrolase activity of the respective BVP proteins. BVP catalysis in vitro was
not limited to 5-phosphorylated RNA or nucleotide substrates, but also embraced tripolyphosphatase and pyrophosphatase
activities. BVP-specific activities with nucleotide and inorganic substrates were as follows: ATP (14 min1), ADP (31 min1),MP. We
r Sciencefold to the hydrolysis of phosphoanhydrides. © 2002 Elsevie
INTRODUCTION
RNA triphosphatase catalyzes the hydrolysis of the 
phosphate of triphosphate-terminated RNA to form a
diphosphate end. Two distinct classes of eukaryotic RNA
triphosphatases have been described (Shuman, 2001,
2002). The RNA triphosphatases of metazoans, plants,
and the iridovirus ISKNV (infectious spleen and kidney
necrosis virus) belong to the cysteine phosphatase su-
perfamily that includes protein tyrosine phosphatases,
dual specificity protein phosphatases, and phosphoino-
sitide phosphatases. The cysteine phosphatase-type
RNA triphosphatases do not require a metal cofactor. In
contrast, the RNA triphosphatases of fungi, protozoa, and
certain DNA viruses (poxviruses, baculoviruses, Chlor-
ella virus) comprise a new family of metal-dependent
phosphohydrolases. There are no mechanistic or struc-
tural similarities whatsoever between the cysteine phos-
phatase and metal-dependent RNA triphosphatase fam-
ilies (Lima et al., 1999; Changela et al., 2001).
The cysteine phosphatase-type RNA triphosphatases
are subdivided into two groups: (i) bifunctional enzymes
composed of an N-terminal RNA triphosphatase domain
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and a C-terminal RNA guanylyltransferase domain and
(ii) monofunctional RNA triphosphatases. The bifunc-
tional enzymes are ubiquitous in metazoans, where they
are responsible for forming the 5-cap structure of cellu-
lar mRNAs (Takagi et al., 1997; Ho et al., 1998a; Wen et
al., 1998; Yokoska et al., 2000). The exemplary bifunc-
tional cysteine phosphatase-type RNA triphosphatase is
the mammalian capping enzyme, Mce1. Among viruses,
only the iridovirus ISKNV encodes a cysteine phospha-
tase-type RNA triphosphatase fused to a guanylyltrans-
ferase (He et al., 2001). The monofunctional enzymes
include human PIR1 phosphatase (Deshpande et al.,
1999) and BVP, a phosphatase encoded by the Autogra-
pha californica baculovirus (Gross and Shuman, 1998;
Takagi et al., 1998). The roles of the monofunctional RNA
triphosphatase enzymes in RNA metabolism are not un-
derstood.
The metal-dependent RNA triphosphatases also fall
into two groups, depending on whether they are physi-
cally linked to the guanylyltransferase component of the
RNA capping apparatus. Several DNA viruses that infect
metazoan species (e.g., poxviruses, African swine fever
virus, and baculoviruses) encode triphosphatase-guany-
lyltransferase enzymes, whereas these two activities are
encoded by separate genes in fungi, microsporidia, Plas-PPPi (3.7 min
1), and PPi (1 min
1). BVP did not hydrolyze A
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modium falciparum, Trypanosoma brucei, and Chlorella
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baculoviruses are unique among DNA viruses in that
they encode two RNA triphosphatases: a bifunctional
metal-dependent enzyme (Lef4) and a monofunctional
cysteine phosphatase-type enzyme (BVP).
It is striking that the physical order of the catalytic
motifs and domains within the primary structures of the
bifunctional proteins is always H2N-triphosphatase-gua-
nylyltransferase-COOH, even where the structures and
mechanisms of the triphosphatase components diverge.
This physical order mimics the temporal order of the
cap-forming reactions. Is this arrangement functionally
significant for the bifunctional capping enzymes?
To answer this question, we exploited the budding
yeast Saccharomyces cerevisiae as a surrogate genetic
model. We and others have shown that expression of the
bifunctional mammalian capping enzyme Mce1 in S. cer-
evisiae complements the growth of yeast cet1 and
ceg1 strains deleted for the endogenous triphos-
phatase (Cet1) or guanylyltransferase (Ceg1) enzymes
(Yue et al., 1997; Ho et al., 1998a,b; Yamada-Okabe et al.,
1998; Changela et al., 2001). Indeed, Mce1 complements
growth of doubly deleted cet1ceg1 strain in which the
mammalian protein is the only source of triphosphatase
and guanylyltransferase activity (Saha et al., 1999). We
report here that inverting the order of the domains of the
mammalian capping enzyme to H2N-guanylyltrans-
ferase-triphosphatase-COOH does not affect its function
in vivo in yeast.
We extended the genetic analysis to the baculovirus
phosphatase BVP. The 168-amino acid A. californica bac-
ulovirus BVP protein displays extensive sequence simi-
larity to the triphosphatase domains of metazoan and
plant capping enzymes (Fig. 1) and to BVP orthologs
encoded by several other baculoviruses, e.g., the nuclear
polyhedrosis viruses of Anagrapha falcifera, Bombyx
mori, Epiphyas postvittana, and Orgyia pseudotsugata.
Purified recombinant BVP hydrolyzes the  phosphate of
triphosphate-terminated RNA (Gross and Shuman,
1998a; Takagi et al., 1998). BPV also hydrolyzes free
NTPs to NDPs. The remarkable feature of BVP is that it
also catalyzes the hydrolysis of NDPs to NMPs and the
conversion of diphosphate-terminated RNA to mono-
phosphate-terminated RNA. Thus, BVP is a triphos-
phatase and a diphosphatase. In contrast, the metazoan
capping enzyme hydrolyzes only the  phosphate of
RNA.
There has been discussion about whether BVP might
play a role in the capping of baculovirus mRNAs. Bacu-
loviruses, which replicate in the nucleus of insect cells,
use host-cell RNA polymerase II to transcribe early
genes, then switch at late times to a virus-encoded
transcription system that includes a DNA-dependent
RNA polymerase and two cap-forming activities—RNA
triphosphatase and RNA guanylyltransferase (Guarino et
al., 1998a,b; Jin et al., 1998; Gross and Shuman, 1998b).
Both capping activities reside within a single polypep-
tide, Lef4, which is one of four subunits of the baculo-
virus-encoded RNA polymerase. Lef4 is essential for
baculovirus replication in cultured insect cells, but it is
not clear whether the requirement for Lef4 reflects its
participation in transcription or RNA capping or both.
BVP is not essential for replication of A. californica NPV
(Li and Miller, 1995), but its RNA triphosphatase activity
could be redundant to the triphosphatase activity of Lef4.
FIG. 1. Structure-based sequence alignment of cysteine phosphatase-type RNA triphosphatases. The amino acid sequences of the N-terminal RNA
triphosphatase domains of mouse capping enzyme (Mus CE), C. elegans capping enzyme (Cel CE), D. melanogaster capping enzyme (Dme CE), X.
laevis capping enzyme (Xla CE), and two capping enzymes of A. thaliana (Ath CE and CE) are aligned to human RNA phosphatase PIR1 and the
baculovirus RNA phosphatase BVP. Gaps in the sequences are indicated by dashes (—). The cysteine phosphatase signature motif (the P-loop) is
indicated. Secondary structure elements of the mammalian RNA triphosphatase (PDB ID code: 1I9S) are shown above the sequence with  helices
depicted as boxes,  strands as arrows, and loops as solid lines. Serial C-terminal deletion mutants of the Mce1 triphosphatase domain were
truncated at the positions indicated by arrowheads () above the sequence. The margin of the BVP C10 mutant is indicated by an arrowhead (Œ)
below the sequence. The 11 residues of BVP subjected to mutational analysis are highlighted in shaded boxes.
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All sequenced baculovirus genomes encode a Lef4 or-
tholog, but this is not the case for BVP.
A key issue is whether a role in mRNA capping can
even be invoked for BVP in light of its dual biochemical
activities as a triphosphatase and a diphosphatase. Ki-
netic analyses of the reaction of BVP with either triphos-
phate-terminated RNA or free NTPs showed that the 
phosphate is hydrolyzed prior to the  phosphate and
that the enzyme acts distributively, i.e., NMP products do
not begin to accumulate until the majority of the input
NTP has been first converted to NDP (Gross and Shu-
man, 1998a). Takagi et al. (1998) reported that BVP was
threefold more active on 5-diphosphate RNA ends than
on 5-triphosphate ends and they suggested that an in
vivo function of BVP may be to generate 5-RNA mono-
phosphate ends, a process that could potentially prevent
the guanylylation of host-cell mRNAs and thereby facili-
tate a shutoff of host protein synthesis. Here we show
that BVP can act as an RNA triphosphatase in the cap
synthetic pathway in vivo. We demonstrate complemen-
tation of S. cerevisiae cet1 by an Mce1(211–597)BVP
fusion protein and we correlate the effects of BVP muta-
tions on triphosphatase function in vitro with BVP’s cap-
ping activity in vivo. We also show that BVP has intrinsic
tripolyphosphatase and pyrophosphatase activities in
vitro, signifying that its substrate specificity extends to
inorganic phosphoanhydrides.
RESULTS
Inverted MCE1 functions in vivo in yeast
The crystal structure of mammalian RNA triphos-
phatase Mce1(1–210) revealed that the enzyme is a glob-
ular monomeric protein with a deep, positively charged
active site pocket that can accommodate a 5-triphos-
phate end (Changela et al., 2001). The structure consists
of five  strands that form a central twisted sheet flanked
by two  helices on one side and four  helices on the
other. The secondary structure elements are shown
above the Mce1 sequence in Fig. 1. The conserved
125HCTHGFNRT133 phosphate-binding loop contains the
active site cysteine nucleophile that forms a phosphoen-
zyme intermediate in the triphosphatase reaction. The
C-terminus of the triphosphatase domain travels back
towards the N-terminus in the tertiary structure, where it
would then lead into the guanylyltransferase domain
[Mce1(211–597)] of the native bifunctional capping en-
zyme. An 11-amino acid C-terminal segment of the
Mce1(1–210) domain was disordered in the crystal struc-
ture, suggesting that the interdomain linker may be flex-
ible in the native full-length Mce1.
To test whether the domain order is important for
capping activity in vivo, we constructed a new version of
mammalian capping enzyme in which the domains were
inverted in the primary structure as Mce1(211–597)–(1–
210). We tested by plasmid shuffle (Boeke et al., 1987)
whether expression of the InvMCE1 gene could comple-
ment cap formation in yeast. MCE1 and InvMCE1 were
cloned into yeast CEN TRP1 plasmids so as to place
their expression under the control of a constitutive pro-
moter. The plasmids were then transformed into a S.
cerevisiae cet1 strain in which the chromosomal CET1
gene was deleted and replaced by LEU2. Growth of
cet1 is contingent on maintenance of a wild-type CET1
allele on a CEN URA3 plasmid. Therefore, the cet1
strain is unable to grow on agar medium containing
5-FOA (5-fluoroorotic acid, a drug which selects against
the URA3 plasmid) unless it is first transformed with a
biologically active RNA triphosphatase gene. We showed
previously that expression of wild-type MCE1 in cet1
cells permitted their growth on 5-FOA, whereas expres-
sion of the catalytically inactive C126S mutant did not (Ho
et al., 1998b). Here we find that InvMCE1 was able to
complement the growth of cet1 cells on 5-FOA (Fig. 2).
Additional control experiments showed that: (i) the
MCE1(1–210) gene encoding only the triphosphatase do-
main was unable to complement cet1; (ii) cet1 cells
cotransformed with two different CEN plasmids, one ex-
pressing MCE1(1–210) and the other expressing
MCE1(211–597), failed to give rise to 5-FOA-resistant
colonies; (iii) cet1MCE1 cells and cet1 InvMCE1 cells
grew as well on rich medium (YPD agar) as CET1 cells at
23, 30, and 37°C; (iv) InvMCE1 also complemented the S.
FIG. 2. Complementation of cet1 by InvMCE1. The cet1 strain
YBS20 (trp1 ura3 leu2 cet1::LEU2 p360-Cet1[CEN URA3 CET1]) was
transformed with CEN TRP1 plasmids bearing wild-type MCE1, Inv-
MCE1 encoding the guanylyltransferase domain (aa 211–597) fused to
the full-length triphosphatase domain (aa 1–210), or mutant InvMCE1
alleles encoding the guanylyltransferase domain fused to truncated
versions of the triphosphatase domain (aa 1–178, 1–162, 1–160, or
1–147). Trp transformants were selected and then patched on agar
medium lacking tryptophan. Cells from single patches were then
streaked on agar medium containing 0.75 mg/ml of 5-fluoroorotic acid
(5-FOA). The plates were photographed after incubation for 4 days at
30°C.
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cerevisiae guanylyltransferase deletion mutant ceg1 in
a plasmid shuffle assay (not shown).
We conclude that whereas the catalytically autono-
mous triphosphatase domain must be linked in cis to
guanylyltransferase in order to function in yeast, the
order of the domains can be inverted without apparent
effect.
Deletion analysis of mammalian RNA triphosphatase
delineates a functional domain boundary
The autonomous mammalian RNA triphosphatase do-
main Mce1(1–210) is 33 amino acids longer at its car-
boxyl end than BVP. To delineate the distal margin of the
functional mammalian triphosphatase domain, we con-
structed a series of C-terminal truncations in the context
of InvMCE1 and tested the mutant alleles by plasmid
shuffle for their activities in vivo in yeast. The C-termini of
the deletion mutants (denoted by arrowheads in Fig. 1)
were chosen based on the Mce1(1–210) crystal structure
so as to truncate the protein in the loops connecting a
series of C-terminal helices, rather than within the heli-
ces themselves.
We found that the MCE1(211–597)–(1–178) allele re-
tained RNA triphosphatase activity in vivo, whereas the
more extensively truncated alleles MCE1(211–597)–(1–
162), MCE1(211–597)–(1–160), and MCE1(211–597)–(1–
147) were unable to complement cet1 (Fig. 2). None-
theless, all of the InvMCE1 C-terminal deletion alleles
were able to complement the guanylyltransferase dele-
tion ceg1. We conclude that: (i) the two helices distal to
position Gly178, which are not present in BVP, do not
contribute significantly to the in vivo RNA triphosphatase
activity of Mce1; (ii) the segment between amino acids
Pro162 and Gly178, which includes an  helix, is essen-
tial for Mce1 function in vivo. A conserved counterpart of
this essential helix is present in BVP (Fig. 1).
BVP can function as a capping enzyme in yeast
BVP has 5-triphosphatase and 5-diphosphatase ac-
tivities in vitro. To probe whether BVP is active as RNA
triphosphatase in vivo in mRNA cap formation, we con-
structed a gene encoding a chimeric enzyme, InvMce1-
BVP, in which the mammalian RNA triphosphatase do-
main of InvMce1 was replaced by the 168-amino acid
BVP polypeptide. We found that InvMCE1-BVP comple-
mented the S. cerevisiae cet1 mutant (Fig. 3) and that
InvMCE1-BVP cells grew as well as InvMCE1 cells on
YPD agar at 30°C (not shown). Additional control exper-
iments showed that: (i) the BVP gene per se was unable
to complement cet1 and (ii) cet1 cells cotransformed
with two different CEN plasmids, one expressing BVP
and the other expressing MCE1(211–597), failed to give
rise to 5-FOA-resistant colonies. We conclude that BVP
can acts as a capping enzyme in vivo, provided it is
linked in cis to guanylyltransferase.
A truncated version InvMCE1-BVP(C10) lacking the
C-terminal 10 amino acids of BVP was unable to com-
plement cet1, although it was able to complement the
guanylyltransferase deletion mutant ceg1 (data not
shown). To evaluate the basis for this effect, we pro-
duced the BVP(C10) protein in bacteria as a His10-
tagged fusion, purified it from a soluble bacterial extract
by Ni-agarose chromatography, and assayed it for nucle-
oside triphosphatase activity as described previously for
wild-type BVP (Martins and Shuman, 2000). We found
that BVP(C10) had no detectable triphosphatase activity
and was unable to form the covalent phosphoenzyme
intermediate (not shown). The C10 deletion is predicted
to embrace the  helix that we showed is essential for
the in vivo function of the mammalian RNA triphos-
phatase (Fig. 1). Thus, it would appear that BVP naturally
comprises a minimal functional domain for the cysteine-
phosphatase type RNA triphosphatase family.
Mutational effects on BVP function in vivo
We had previously characterized the biochemical ac-
tivities of a collection of 23 BVP mutants containing either
alanine or conservative substitutions in lieu of seven
individual amino acids within the phosphate-binding
loop (117-VHCTHGINRTGY-128) (Fig. 1) (Martins and Shu-
man, 2000). In order to correlate BVP activity in vivo with
its triphosphatase activity in vitro, we introduced the 23
mutations into InvMCE1-BVP and tested them by plasmid
shuffle for function in vivo. The complementation data are
summarized in Table 1, which also includes the ATPase
activities of the recombinant BVP mutant proteins, ex-
FIG. 3. Complementation of cet1 by InvMCE1-BVP. The cet1 strain
was transformed with CEN TRP1 plasmids bearing “wild-type” Inv-
MCE1-BVP or InvMCE1-BVP alleles containing missense mutations in
the P-loop of the BVP domain. Trp transformants were selected and
then patched on agar medium lacking tryptophan. Cells from single
patches were then streaked on agar medium containing 0.75 mg/ml of
5-fluoroorotic acid (5-FOA). The plates were photographed after incu-
bation for 4 days at 30°C.
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pressed as the percentage of the wild-type BVP specific
activity.
Three mutations of the active site cysteine nucleo-
phile—C119A, C119V, and C119S—abolished BVP’s cap-
ping function in vivo, consistent with the complete loss of
triphosphatase catalytic activity in vitro as a conse-
quence of these mutations. Three different mutations of
P-loop residues His118 (H118A, H118V, H118N) and
Asn124 (N124A, N124Q, N124D) abrogated BVP function
in vivo, just as they eliminated BVP phosphohydrolase
activity in vitro. Three different mutations at His121
(H121A, H121Q, H121N) and two mutations at Arg125
(R125A and R125K) in the P-loop also inactivated BVP in
vivo, even though two of the mutant enzymes (H121N and
R125K) displayed 8–10% residual triphosphatase activity
in vitro compared to wild-type BVP (Table 1).
BVP activity in vivo was eliminated by the T120A mu-
tation, but was revived when either a valine or serine
was introduced at Thr120. The T120S change conferred a
temperature-sensitive growth phenotype. The gains of
function in vivo correlated with complete restoration of
triphosphatase activity in vitro for T120V and partial res-
toration for T120S (to 26% of wild-type activity compared
to 7% for T120A). Changing Thr126 to valine abolished
BVP capping activity in vivo and triphosphatase activity in
vitro, whereas the introduction of a serine restored
complementation of cet1 and triphosphatase activity in
vitro to 65% of wild type. The T126A mutant was func-
tional in vivo, although we had reported previously that
recombinant T126A protein displayed no detectable
ATPase activity in vitro (Martins and Shuman, 2000).
Subsequent analysis of the original T126A preparation
showed that it was prone to precipitate from solution
during storage. We have since produced and purified
three separate preparations of recombinant T126A and
found that each of the T126A preparations was 8% as
active as wild-type BVP in the hydrolysis of ATP. Thus, the
original report of complete inactivation by the T126A
change was incorrect and the activity of T126A in vivo is
consistent with the revised in vitro data showing residual
catalytic activity of the T126A protein. Replacement of
Tyr128 with alanine was lethal in vivo, whereas the Y128F
and Y128L changes restored cet1 complementation,
just as they revived the catalytic activities of the recom-
binant BVP proteins (to 32% of wild-type in the case of
Y128L).
A second set of five mutants in residues Asp60, Asp69,
and Asp101 located upstream of the P-loop had been
characterized biochemically and these mutations were
also introduced into InvMCE1-BVP and tested for func-
tion in vivo in yeast. D69A and D101A were active in vivo,
just as they were in vitro. Changing Asp60, which is
conserved in all of the cysteine-phosphatase type RNA
triphosphatases (Fig. 1), to either alanine or asparagine
did not affect BVP capping activity in vivo, consistent with
the lack of deleterious effects on triphosphatase activity
in vitro. However, the introduction of a bulkier glutamic
acid at position 60 abolished BVP activity in vivo, just as
it eliminated catalytic activity in vitro (Table 1).
In concert, these results suggest that a threshold level
of BVP catalytic activity is needed to support cap forma-
tion in vivo in yeast.
TABLE 1
Mutational Effects of BVP Activity in Vivo and in Vitro
InvMce1-BVP
mutant
Complementation
BVP ATPase
(% of WT)cet1 ceg1
D60A   95
D60N   59
D60E   1
D69A   65
D101A   200
H118A   0.1
H118V   0.1
H118N   0.1
C119A   0.1
C119V   0.1
C119S   0.1
T120A   7
T120V   200
T120S ts  26
H121A   0.1
H121Q   2
H121N   8
N124A   0.1
N124Q   0.1
N124D   0.1
R125A   0.1
R125K   10
T126A   8
T126V   0.1
T126S   65
Y128A   0.1
Y128F   160
Y128L   32
Note. The in vivo activity of the mutated BVP alleles in complemen-
tation of the yeast cet1 and ceg1 deletions was tested by plasmid
shuffle. The cet1 strain was transformed with pYX-InvMce1-BVP plas-
mids. Trp isolates were selected and then streaked on agar plates
containing 0.75 mg/ml of 5-fluoroorotic acid (5-FOA). Growth was
scored after 7 days of incubation at 23, 30, and 37°C. Lethal mutants
(scored as ) were those that failed to form colonies on 5-FOA at any
temperature. Individual colonies of the viable mutant strains were
picked from the 5-FOA plate at permissive temperature and patched to
YPD agar. Two isolates of each mutant were tested for growth on YPD
agar at 23, 30, and 37°C. Growth was assessed as follows: 
indicates colony size indistinguishable from strains bearing wild-type
InvMCE1-BVP; ts indicates growth at 23 and 30°C, but not at 37°C. All
of the pYX-InvMce1-BVP plasmids were capable of complementing the
growth of a ceg1 strain in a plasmid shuffle assay (scored as ).
The ATPase specific activities of the purified recombinant mutant His10-
BVP proteins are from Martins and Shuman (2000) or, for T126A, new
titration experiments (not shown).
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BVP substrate specificity
BVP displays a robust 5-triphosphatase and 5-
diphosphatase activity with either RNA or mononucle-
otide substrates (Gross and Shuman, 1998; Takagi et al.,
1998). The question arises whether BVP actually requires
a nucleoside constituent for its phosphohydrolase activ-
ity; i.e., can BVP act on inorganic phosphoanhydride
substrates such as tripolyphosphate (PPPi) and pyro-
phoshate (PPi)? We employed a colorimetric assay to
measure BVP-catalyzed release of inorganic phosphate
from unlabeled PPPi or PPi. Reactions containing equiv-
alent concentrations of unlabeled ATP or ADP served as
positive controls.
The extent of Pi release from each substrate was
proportional to the amount of input BVP (not shown).
From the slopes of the titration curves in the range where
20% of the input ATP had been hydrolyzed (i.e., under
conditions in which virtually all Pi is released from ATP
and not ADP), we calculated an ATPase turnover number
of 14 min1 (Table 2). BVP was twice as active with ADP,
displaying an ADPase turnover number of 31 min1. BVP
catalyzed no detectable release of Pi from AMP (Table 2).
The higher activity with ADP than ATP agrees with the
previous report that BVP activity toward 5-diphosphate
RNA was 3-fold higher than its activity on 5-triphosphate
RNA (Takagi et al., 1998).
The instructive finding was that BVP did catalyze the
release of Pi from tripolyphosphate, albeit less effectively
than it hydrolyzed ATP. The turnover number for the
tripolyphosphatase activity of BVP was 3.7 min1 (about
one-fourth of its ATPase activity). BVP also catalyzed the
hydrolysis of PPi to Pi, with a turnover number of 1 min
1
(corresponding to 7, 3 and 27% of its ATPase, ADPase
and tripolyphosphatase activities, respectively). In calcu-
lating the pyrophosphatase specific activity, we halved
the extent of Pi formation to correct for the fact that two
molecules of Pi are produced for each molecule of PPi
hydrolyzed. The ATPase, ADPase, tripolyphosphatase,
and pyrophosphatase activities were intrinsic to recom-
binant BVP, because the C119S mutant protein was com-
pletely inactive in releasing Pi from any of these sub-
strates (not shown).
DISCUSSION
Mce1 and BVP belong to the cysteinyl phosphatase
family of RNA triphosphatases. The biological function of
Mce1 in mammalian mRNA capping is generally ac-
cepted, although a formal genetic proof (entailing condi-
tional gene inactivation of Mce1 in mammalian cells) is
not in hand. In the meantime, the budding yeast S.
cerevisiae provides a convenient surrogate system to
test the structural requirements for Mce1 function in vivo.
We had shown previously that the N-terminal triphos-
phatase and C-terminal guanylyltransferase domains
were fully autonomous with respect to catalysis in vitro,
yet the two domains had to be fused in order for Mce1 to
function in vivo in yeast (Ho et al., 1998a,b). Here we
tested whether the linear order of the triphosphatase and
guanylyltransferase domains of Mce1 mattered in vivo.
This question was prompted by the universal conserva-
tion of domain order in all known bifunctional capping
enzymes, whether of cellular, viral, or plasmid origin
(Shuman, 2001, 2002), and irrespective of whether the
triphosphatase component employs a cysteinyl-phos-
phatase-type or metal-dependent catalytic mechanism.
Our results show that there is no obligate domain order
for Mce1 function in vivo, at least not in yeast. It is
conceivable that the natural domain order confers some
advantage in metazoans that is not apparent when yeast
is used as the tester organism.
The biological activity of the InvMce1 protein allowed
us to determine by deletion analysis the distal margins of
the mammalian triphosphatase domain. We felt that the
interpretation of deletion effects was potentially more
straightforward in InvMce1, because internal deletions of
the standard Mce1 construct might affect function indi-
rectly by altering the spacing between the triphos-
phatase and guanylyltransferase domains. This was not
an issue in the InvMce1 system. We found that Mce1(1–
178) comprises a functional triphosphatase domain and
deletion to position 162 results in loss of function in vivo.
Wen et al. (1998) reported that a GST fusion of Mce1(1–
162) retained RNA triphosphatase activity in vitro. The
apparent discrepancy between the minimal domains for
in vitro and in vivo function may indicate a role for the
segment from 163 to 178 (which embraces conserved
helix 8) in ensuring proper folding and stability of Mce1
in vivo. The crystal structure of the Mce1 triphosphatase
shows that helix 8 makes extensive contacts with he-
lices 5 and 6 (with the 6 helix contributing two
essential catalytic residues to the active site) (Changela
et al., 2001). In addition, the Arg160 side chain, which is
near the margin of the deletion that inactivates Mce1 in
vivo, directly coordinates the main chain carbonyls of the
P-loop and is important for thermal stability of Mce1; i.e.,
TABLE 2
BVP Substrate Specificity
Substrate Phosphatase activity (min1)
ATP 14 3
ADP 31 5
AMP 0.05
PPPi 3.7 0.5
PPi 1.0 0.2
Note. The specific activities for BVP-catalyzed Pi release were cal-
culated from the slopes of the protein titration curves in the range
corresponding to hydrolysis of 20% of the input substrate. The activ-
ities are expressed as a turnover numbers (min1); each value is the
average of four independent titration experiments ( mean error).
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the R160A mutation inactivates Mce1 function at 37°C in
vivo (Changela et al., 2001). We attempted to produce
recombinant Mce1(1–162) in bacteria as a His-tagged
fusion and a GST fusion, but obtained only insoluble
protein.
The minimum in vivo functional domain of the mam-
malian RNA triphosphatase corresponds almost exactly
to the full-length baculovirus BVP according to the struc-
ture-based sequence alignment in Fig. 1. BVP is nones-
sential for baculovirus replication and its potential role
as a cap-forming enzyme has been questioned in light of
its intrinsic RNA diphosphatase activity. However, be-
cause BVP removes the  and  phosphates sequentially
and distributively, there is no a priori reason that BVP
could not process RNA ends for capping, provided that
the guanylyltransferase reaction occurred in a timely
fashion. Here we showed that BVP can act as a cap-
forming enzyme in vivo when fused to the C-terminal
guanylyltransferase domain of the mammalian capping
enzyme. We infer that the RNA diphosphatase activity of
BVP does not preclude timely guanylylation of nascent
pre-mRNAs.
By testing a battery of biochemically characterized
BVP mutants for capping function in yeast, we found that:
(i) any mutation that reduced triphosphatase activity in
vitro to 2% of wild-type abrogated BVP activity in vivo;
(ii) mutants that retained at least one-fourth of wild-type
activity in vitro were functional in vivo; (iii) the T126A
mutant, which retained 8% of wild-type triphosphatase
activity, was active in vivo; and (iv) other mutants with low
residual activity in vitro (T120A, H121N, R125K) were
nonfunctional in vivo. We conclude that whereas a
threshold level of triphosphatase activity is required for
BVP function in yeast, the retention of triphosphatase
activity in the range of 10% of wild-type does not inevi-
tably suffice for in vivo function. Other factors such as
mutational effects on protein stability or substrate bind-
ing affinity in vivo may come into play in such cases. The
key point is that InvMce1 fusions and yeast genetics can
be used to assess structure-activity relationships for
heterologous RNA triphosphatases, including the “mono-
functional” class of cysteinyl phosphatase-type enzymes
like BVP, PIR1, and their homologs, for which a physio-
logical substrate and function is not clearly defined.
Our finding that BVP is capable of hydrolyzing inor-
ganic tripolyphosphate and pyrophosphate provides new
insight to its substrate specificity, showing that the en-
zyme can act on phosphoanhydrides that lack a nucleo-
side component. Yet, BVP was unable to hydrolyze the
phosphomonoester linkage of AMP. The failure of BVP to
release Pi from AMP may reflect: (i) intrinsic preference
for hydrolysis of phosphoanhydrides over phosphomo-
noesters, or (ii) inaccessibility of the AMP phosphate to
the cysteine thiolate nucleophile, which is located at the
deep end of the active site pocket (Changela et al., 2001).
Variable depth of the active site pocket in Mce1 (deeper
pocket) versus BVP (shallower pocket) has been invoked
to explain the specificity of Mce1 for cleaving only the 
phosphate of RNA. It is conceivable that the BVP active
site is nonetheless too deep to allow penetration of the
AMP phosphate to within striking distance of Cys119.
MATERIALS AND METHODS
Yeast vectors encoding inverted mammalian capping
enzyme, Mce1(211–597)–Mce1(1–210)
A yeast CEN plasmid encoding an inverted mamma-
lian capping enzyme (InvMce1) composed of the mam-
malian guanylyltransferase domain Mce1(211–597) fused
to the mammalian triphosphatase domain Mce1(1–210)
was constructed in three stages as follows. (i) The cod-
ing sequence of the triphosphatase domain was ampli-
fied by PCR from plasmid pET16-Mce1(1–210) (Ho et al.,
1998a) using a sense-strand primer (primer S1) coding
for a 5-fusion junction LHRPTMAYNKIPP, wherein
MAYNKIPP comprises amino acids 1 to 8 of the native
Mce1. The sense primer also introduced a StuI site at the
Arg-Pro codons of the fusion junction. The antisense
primer corresponded to the T7 terminator sequence of
the plasmid template. The coding sequence of the gua-
nylyltransferase domain was amplified by PCR from plas-
mid pET16-Mce1(211–597) using an antisense-strand
primer (primer A1) that replaced the stop codon with an
ATG methionine codon to from a 3-fusion junction
LHRPTM, where LHRPT corresponds to amino acids 593
to 597 of native Mce1. The antisense sense primer also
introduced a StuI site at the Arg-Pro codons of the 3-
fusion junction. The sense strand primer corresponded
to the T7 promoter sequence of the plasmid template. (ii)
The purified first-stage PCR products encoding the indi-
vidual domains with complementary overlaps were
mixed and the InvMCE1 fusion gene was generated by a
second round of PCR amplification with T7 promoter and
T7 terminator primers. (iii) The InvMCE1 fusion product
was digested with NdeI and BamHI and inserted into the
modified yeast expression vector pYX1 (CEN TRP1), a
derivative of pYX132 (Novagen) that encodes six tandem
histidines and a unique NdeI site between the NcoI and
BamHI sites. Expression of InvMCE1 in this plasmid is
under the control of the yeast TPI1 promoter. The insert
of pYX-InvMce1 was sequenced completely to confirm
the in-frame fusions and to exclude the introduction of
unwanted coding changes during amplification and clon-
ing.
Deletion mutants of the triphosphatase component of
InvMce1
DNAs encoding C-terminal truncation mutants of the
mammalian triphosphatase domain were prepared by
PCR amplification using primer S1 and various muta-
genic antisense-strand primers that introduced a trans-
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lation stop codon in lieu of the codons for Asp179,
Gly163, Pro161, or Ser148, plus a BamHI site immediately
3 of the new stop codon. The PCR products were di-
gested with StuI and BamHI and then inserted into pYX-
InvMce1 in place of the wild-type StuI-BamHI fragment.
Yeast vectors encoding Mce1(211–597)-BVP fusion
proteins
A yeast CEN plasmid encoding a chimeric Mce1(211–
597)-BVP fusion protein (InvMce1-BVP) was constructed
as follows. (i) The BVP gene was amplified from pET16-
BVP (Gross and Shuman, 1998a) using the T7 terminator
antisense primer and a sense-strand primer (primer S2)
coding for a 5-fusion junction RPTMFPA, wherein MFPA
comprises amino acids 1 to 4 of the native BVP. The
sense primer also introduced a StuI site at the Arg-Pro
codons of the fusion junction. (ii) The PCR product en-
coding BVP was digested with StuI and BamHI and then
inserted into pYX-InvMce in place of the StuI-BamHI
fragment encoding mammalian triphosphatase. The in-
sert of pYX-InvMce1-BVP was sequenced completely to
confirm the in-frame fusion and to exclude the introduc-
tion of unwanted coding changes during amplification
and cloning. Mutated versions of the BVP gene that had
been cloned into pET-based plasmids (Martins and Shu-
man, 2000) were PCR-amplified using the T7 and S2
primers and then cloned into the pYX-InvMce1-BVP in
place of the wild-type BVP fragment.
Purification of wild-type BVP
A 1-liter culture of E. coli BL21(DE3)pLysS/pET16-BVP
was grown at 37°C in LB medium containing 0.1 mg/ml
ampicillin and 30 g/ml chloramphenicol until the A600
reached 0.6. The culture was adjusted to 0.1 mM IPTG
and incubation was continued for 3 h at 30°C with
constant shaking. The cells were harvested by centrifu-
gation and recombinant BVP was purified from the sol-
uble bacterial extract by Ni-agarose chromatography as
described previously (Gross and Shuman, 1998; Martins
and Shuman, 2000). The enzyme preparation was dia-
lyzed against buffer containing 50 mM Tris-HCl (pH 8.0)
200 mM NaCl, 2 mM DTT, 10% glycerol, 0.1% Triton X-100
and stored at 80°C. The yield of recombinant BVP was
15 mg per liter of induced bacteria.
Tripolyphosphatase/pyrophosphatase assay
Phosphohydrolase reaction mixtures (25 l) contain-
ing 50 mM Tris-HCl (pH 7.0), 5 mM DTT, 2 mM tripolypho-
sphate (or pyrophosphate or ATP or ADP or AMP), and
serial twofold dilutions of BVP were incubated for 15 min
at 30°C. The reactions were quenched by adding 1 ml of
malachite green reagent (Biomol Green reagent, pur-
chased from Biomol Research Laboratories, Plymouth
Meeting, PA). Phosphate release was determined by
measuring A620 and extrapolating the value to a phos-
phate standard curve. Background levels of inorganic
phosphate (typically 3–6% of the input levels of PPPi, PPi,
ATP, or ADP substrate) determined from the A620 of a
control reaction mixture lacking BVP were subtracted
from the values measured for the reactions containing
BVP.
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